Document


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): May 3, 2018
 logo1a01.jpg
(Exact name of registrant as specified in its charter)
 

Delaware
 
000-55039
 
46-2568498
(State or other jurisdiction
 
(Commission
 
(I.R.S. Employer
of incorporation)
 
File Number)
 
Identification No.)
 

1000 Cedar Hollow Road
Malvern, Pennsylvania
 
19355
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (610) 729-7000
 
 
Former name or former address, if changed since last report
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company o
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o






Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 3, 2018, BioTelemetry, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders adopted the following proposals and cast their votes as described below.
Proposal 1
Election of two Class II director nominees to hold office until the 2021Annual Meeting of Stockholders or until their successors are elected and qualified:
 
 
 
 
 
 
 
Broker
 
For
 
Against
 
Abstained
 
Non-Vote
Anthony J. Conti
21,733,773
 
806,147
 
24,642
 
4,517,605
Kirk E. Gorman
22,207,955
 
332,412
 
24,195
 
4,517,605
Proposal 2
Vote on an advisory resolution to approve the compensation of the Company’s named executive officers:
 
 
 
 
 
 
 
Broker
 
For
 
Against
 
Abstained
 
Non-Vote
 
21,761,514
 
759,525
 
43,523
 
4,517,605
Proposal 3
Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered accounting firm for the year ending December 31, 2018:
 
 
 
 
 
 
 
Broker
 
For
 
Against
 
Abstained
 
Non-Vote
 
25,828,171
 
1,214,928
 
39,068
 







SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BioTelemetry, Inc.
 
 
 
 
 
 
 
 
May 4, 2018
 
By:
/s/ Peter Ferola
 
 
 
 
 
 
 
Name:
Peter Ferola
 
 
 
Title:
Senior Vice President and General Counsel